Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 96

1.

Reply to "Metronomic chemotherapy beyond misconceptions"--Haematologica 2013;98(11):e145.

Papanikolaou X, Heuck CJ, Barlogie B.

Haematologica. 2013 Nov;98(11):e149-50. doi: 10.3324/haematol.2013.098939. No abstract available.

PMID:
24186320
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Metronomic chemotherapy beyond misconceptions.

Hatzimichael E, Briasoulis E.

Haematologica. 2013 Nov;98(11):e145. doi: 10.3324/haematol.2013.096917. No abstract available.

PMID:
24186318
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma.

Papanikolaou X, Szymonifka J, Rosenthal A, Heuck CJ, Mitchell A, Johann D Jr, Keller J, Waheed S, Usmani SZ, Van Rhee F, Bailey C, Petty N, Hoering A, Crowley J, Barlogie B.

Haematologica. 2013 Jul;98(7):1147-53. doi: 10.3324/haematol.2013.085183. Epub 2013 May 28.

PMID:
23716540
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program.

Steurer M, Spizzo G, Mitterer M, Gastl G.

Onkologie. 2004 Apr;27(2):150-4.

PMID:
15138347
[PubMed - indexed for MEDLINE]
5.

New hope for relapsed and refractory multiple myeloma.

Leleu X.

Lancet Oncol. 2013 Oct;14(11):1028-9. doi: 10.1016/S1470-2045(13)70399-1. Epub 2013 Sep 3. No abstract available.

PMID:
24007745
[PubMed - indexed for MEDLINE]
6.

Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety.

Lee SS, Suh C, Kim BS, Chung J, Joo YD, Ryoo HM, Do YR, Jin JY, Kang HJ, Lee GW, Lee MH, Shim H, Kim K, Yoon SS, Bang SM, Kim HY, Lee JJ, Park J, Lee DS, Lee JH; Korean Multiple Myeloma Working Party.

Ann Hematol. 2010 Sep;89(9):905-12. doi: 10.1007/s00277-010-0943-z. Epub 2010 Mar 27.

PMID:
20349060
[PubMed - indexed for MEDLINE]
7.

Velcade, Doxil and Thalidomide (VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma.

Chanan-Khan A, Miller KC.

Leuk Lymphoma. 2005 Jul;46(7):1103-4. No abstract available.

PMID:
16019567
[PubMed - indexed for MEDLINE]
8.

Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation.

Trieu Y, Trudel S, Pond GR, Mikhael J, Jaksic W, Reece DE, Chen CI, Stewart AK.

Mayo Clin Proc. 2005 Dec;80(12):1578-82.

PMID:
16342650
[PubMed - indexed for MEDLINE]
9.

Phase II study of topotecan and cyclophosphamide in patients with relapsed and refractory multiple myeloma.

Kraut EH, Young D, Farag S, James AG, Solove RJ.

Leuk Res. 2005 Oct;29(10):1233-4. Epub 2005 Apr 1. No abstract available.

PMID:
16111541
[PubMed - indexed for MEDLINE]
10.

Panobinostat for the treatment of multiple myeloma.

Rajkumar SV.

Lancet Oncol. 2014 Oct;15(11):1178-9. doi: 10.1016/S1470-2045(14)70443-7. Epub 2014 Sep 18. No abstract available.

PMID:
25242046
[PubMed - indexed for MEDLINE]
11.

Carfilzomib in multiple myeloma: gold, silver, or bronze?

Reece DE.

Blood. 2012 Oct 4;120(14):2776-7. doi: 10.1182/blood-2012-08-446534.

PMID:
23043023
[PubMed - indexed for MEDLINE]
Free Article
12.

Histone deacetylase inhibitors in multiple myeloma.

Pratt G.

Lancet Oncol. 2013 Oct;14(11):1038-9. doi: 10.1016/S1470-2045(13)70425-X. Epub 2013 Sep 19. No abstract available.

PMID:
24055413
[PubMed - indexed for MEDLINE]
13.

Frail elderly patients with relapsed-refractory multiple myeloma: efficacy and toxicity profile of the combination of bortezomib, high-dose dexamethasone, and low-dose oral cyclophosphamide.

Mele G, Giannotta A, Pinna S, Loseto G, Coppi MR, Brocca CM, Melpignano A, Quarta G.

Leuk Lymphoma. 2010 May;51(5):937-40. doi: 10.3109/10428191003695660. No abstract available.

PMID:
20350279
[PubMed - indexed for MEDLINE]
14.

Treatment for elderly patients with multiple myeloma.

Tsubokura M, Kami M.

Lancet. 2008 Mar 22;371(9617):983; author reply 984-5. doi: 10.1016/S0140-6736(08)60443-2. No abstract available.

PMID:
18358919
[PubMed - indexed for MEDLINE]
15.

Novel therapies for relapsed/refractory multiple myeloma: how can we improve on "salvage" therapy?--introduction.

Jakubowiak A.

Semin Hematol. 2012 Jul;49 Suppl 1:S1-2. doi: 10.1053/j.seminhematol.2012.05.002. No abstract available.

PMID:
22727388
[PubMed - indexed for MEDLINE]
16.

Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma.

White D, Kassim A, Bhaskar B, Yi J, Wamstad K, Paton VE.

Cancer. 2013 Jan 15;119(2):339-47. doi: 10.1002/cncr.27745. Epub 2012 Jul 18.

PMID:
22811009
[PubMed - indexed for MEDLINE]
Free Article
17.

Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom).

Knop S, Gerecke C, Liebisch P, Topp MS, Platzbecker U, Sezer O, Vollmuth C, Falk K, Glasmacher A, Maeder U, Einsele H, Bargou RC.

Blood. 2009 Apr 30;113(18):4137-43. doi: 10.1182/blood-2008-10-184135. Epub 2009 Jan 30.

PMID:
19182205
[PubMed - indexed for MEDLINE]
Free Article
18.

Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034).

Prince HM, Hönemann D, Spencer A, Rizzieri DA, Stadtmauer EA, Roberts AW, Bahlis N, Tricot G, Bell B, Demarini DJ, Benjamin Suttle A, Baker KL, Pandite LN.

Blood. 2009 May 7;113(19):4819-20. doi: 10.1182/blood-2009-02-207209. No abstract available.

PMID:
19423744
[PubMed - indexed for MEDLINE]
Free Article
19.

Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma.

Fouquet G, Tardy S, Demarquette H, Bonnet S, Gay J, Debarri H, Herbaux C, Guidez S, Michel J, Perrot A, Serrier C, Miljkovic D, Avet Loiseau H, Facon T, Hulin C, Leleu X.

Cancer. 2013 Oct 15;119(20):3680-6. doi: 10.1002/cncr.28274. Epub 2013 Aug 6.

PMID:
23921945
[PubMed - indexed for MEDLINE]
20.

Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma.

Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, Neil J, Reis I, Kharfan-Dabaja M, Eckman J, Goodman M, Fernandez HF, Boise LH, Lee KP.

Clin Cancer Res. 2002 Dec;8(12):3658-68.

PMID:
12473574
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk